Carregant...
Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma
BACKGROUND: The incidence of stage I and stage II lung adenocarcinoma (LUAD) is likely to increase with the introduction of annual screening programs for high-risk individuals. We aimed to identify a reliable prognostic signature with immune-related genes that can predict prognosis and help making i...
Guardat en:
| Publicat a: | J Transl Med |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7542703/ https://ncbi.nlm.nih.gov/pubmed/33028329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02545-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|